BD PharmingenTM APC Rat Anti-Mouse IFN-gamma

Description

Expression of IFN-gamma by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA 5 ng/ml final concentration; Sigma Cat. #P-8139 and Ionomycin 500 ng/ml final concentration; Sigma Cat. #I0634 in the presence of GolgiPlug Protein Transport Inhibitor 1 mul/ml, Cat. No. 555029 . The splenocytes were harvested and stained with 0.06 mug of FITC Rat Anti-Mouse CD4 FITC-Rm4-5, Cat. No. 553047 , fixed, permeabilized and subsequently stained with 0.12 mug of APC Rat IgG1 isotype control antibody APC-R3-34, Cat. No. 554686, left panel or with APC Rat Anti-Mouse IFN-gamma APC-XMG1.2, Cat. No. 554413, middle panel by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody 5.0 mug; Cat. No. 554409, right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control. Expression of IFN-gamma by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA 5 ng/ml final concentration; Sigma Cat. #P-8139 and Ionomycin 500 ng/ml final concentration; Sigma Cat. #I0634 in the presence of GolgiPlug Protein Transport Inhibitor 1 mul/ml, Cat. No. 555029 . The splenocytes were harvested and stained with 0.06 mug of FITC Rat Anti-Mouse CD4 FITC-Rm4-5, Cat. No. 553047 , fixed, permeabilized and subsequently stained with 0.12 mug of APC Rat IgG1 isotype control antibody APC-R3-34, Cat. No. 554686, left panel or with APC Rat Anti-Mouse IFN-gamma APC-XMG1.2, Cat. No. 554413, middle panel by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody 5.0 mug; Cat. No. 554409, right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control. Expression of IFN-gamma by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA 5 ng/ml final concentration; Sigma Cat. #P-8139 and Ionomycin 500 ng/ml final concentration; Sigma Cat. #I0634 in the presence of GolgiPlug Protein Transport Inhibitor 1 mul/ml, Cat. No. 555029 . The splenocytes were harvested and stained with 0.06 mug of FITC Rat Anti-Mouse CD4 FITC-Rm4-5, Cat. No. 553047 , fixed, permeabilized and subsequently stained with 0.12 mug of APC Rat IgG1 isotype control antibody APC-R3-34, Cat. No. 554686, left panel or with APC Rat Anti-Mouse IFN-gamma APC-XMG1.2, Cat. No. 554413, middle panel by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody 5.0 mug; Cat. No. 554409, right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control. Show More Expression of IFN-gamma by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA 5 ng/ml final concentration; Sigma Cat. #P-8139 and Ionomycin 500 ng/ml final concentration; Sigma Cat. #I0634 in the presence of GolgiPlug Protein Transport Inhibitor 1 mul/ml, Cat. No. 555029 . The splenocytes were harvested and stained with 0.06 mug of FITC Rat Anti-Mouse CD4 FITC-Rm4-5, Cat. No. 553047 , fixed, permeabilized and subsequently stained with 0.12 mug of APC Rat IgG1 isotype control antibody APC-R3-34, Cat. No. 554686, left panel or with APC Rat Anti-Mouse IFN-gamma APC-XMG1.2, Cat. No. 554413, middle panel by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody 5.0 mug; Cat. No. 554409, right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control. Show More Expression of IFN-gamma by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA 5 ng/ml final concentration; Sigma Cat. #P-8139 and Ionomycin 500 ng/ml final concentration; Sigma Cat. #I0634 in the presence of GolgiPlug Protein Transport Inhibitor 1 mul/ml, Cat. No. 555029 . The splenocytes were harvested and stained with 0.06 mug of FITC Rat Anti-Mouse CD4 FITC-Rm4-5, Cat. No. 553047 , fixed, permeabilized and subsequently stained with 0.12 mug of APC Rat IgG1 isotype control antibody APC-R3-34, Cat. No. 554686, left panel or with APC Rat Anti-Mouse IFN-gamma APC-XMG1.2, Cat. No. 554413, middle panel by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody 5.0 mug; Cat. No. 554409, right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control. Expression of IFN-gamma by stimulated CD4+ and CD4-C3H spleen cells. Splenocytes from C3H mice were stimulated in culture for 4 hours using PMA 5 ng/ml final concentration; Sigma Cat. #P-8139 and Ionomycin 500 ng/ml final concentration; Sigma Cat. #I0634 in the presence of GolgiPlug Protein Transport Inhibitor 1 mul/ml, Cat. No. 555029 . The splenocytes were harvested and stained with 0.06 mug of FITC Rat Anti-Mouse CD4 FITC-Rm4-5, Cat. No. 553047 , fixed, permeabilized and subsequently stained with 0.12 mug of APC Rat IgG1 isotype control antibody APC-R3-34, Cat. No. 554686, left panel or with APC Rat Anti-Mouse IFN-gamma APC-XMG1.2, Cat. No. 554413, middle panel by using the BD Pharmingen staining protocol. To demonstrate specificity of staining, the binding by the APC-XMG1.2 antibody was blocked by preincubation of the fixed, premeabilized cells with unlabeled XMG1.2 antibody 5.0 mug; Cat. No. 554409, right panel prior to staining. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the unlabeled antibody blocking specificity control.